{'fraction_non_alphanumeric': 0.039603960396039604, 'fraction_numerical': 0.02263083451202263, 'mean_word_length': 5.87378640776699, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

1T Cell Therapeutics Research Laboratory, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 2Seattle Cancer Care Alliance, Seattle, WA 3Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN 4The University of Texas MD Anderson Cancer Center, Houston, TX 5Premiere Oncology of Arizona, Scottsdale, AZ 6Phi Consulting Group, Bellevue, WA 7IGM Biosciences, Mountain View, CA 8Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA